Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on Tuesday in which the company reported detailed data from the Phase II/III N-MOmentum trial of the humanized mAb against CD19 in the indication.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,